Skip to main content

Table 2 Patients’ clinicopathologic parameters

From: Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer

  In situ(n = 68), n(%) Ex situ(n = 118), n(%) Splenectomy(n = 31),n(%) Pvalue
Gender     0.238
 Male 47(69.1) 91(77.1) 26(83.9)  
 Female 21(30.9) 27(22.9) 5(16.1)  
Age     1.000
  < 60 36(52.9) 63(53.4) 17(54.8)  
  ≥ 60 32(47.1) 55(46.6) 14(45.2)  
BMI     0.716
  < 19 5(7.4) 10(8.5) 1(3.2)  
  ~ <25 46(67.6) 83(70.3) 22(71.0)  
  ~ <30 17(25) 22(18.6) 7(22.6)  
  ≥ 30 0(0) 3(2.5) 1(3.2)  
NACT     0.008
 No 42(61.8) 48(40.7) 11(35.5)  
 Yes 26(38.2) 70(59.3) 20(64.5)  
Degree of LND     0.090
 D1+ 5(7.4) 7(5.9) 1(3.2)  
 D2 58(85.3) 84(71.2) 23(74.2)  
 D2+ 5(7.4) 27(22.9) 7(22.6)  
Gastrectomy     0.033
 Proximal 28(41.2) 34(28.8) 5(16.1)  
 Total 40(58.8) 84(71.2) 26(83.9)  
Differentiation     0.115
 Well 1(1.5) 9(7.6) 5(16.1)  
 Moderate 31(45.6) 53(44.1) 12(38.7)  
 Poor 36(52.9) 57(48.3) 14(45.2)  
LVI     0.060
 No 26(38.8) 66(55.9) 12(41.4)  
 Yes 41(61.2) 52(44.1) 17(58.6)  
Location     0.648
 EGJ 35(51.5) 63(53.4) 12(38.7)  
 U/UM 7(10.3) 10(8.5) 6(19.4)  
 M/MU 24(35.3) 43(36.4) 12(38.7)  
 EUM 2(2.9) 2(1.7) 1(3.2)  
Tumor size     0.548
  ≤ 2 cm 7(10.3) 10(8.5) 2(6.5)  
  ~ ≤5 cm 35(51.5) 56(47.5) 10(32.2)  
  ~ ≤10 cm 21(30.9) 40(33.9) 14(45.2)  
  > 10 cm 5(7.4) 12(10.2) 5(16.1)  
Multi-tumor     0.095
 No 68(100) 115(97.5) 29(93.5)  
 Yes 0 3(2.5) 2(6.5)  
T stagea     0.059
 T2 5(7.4) 11(9.3) 2(6.5)  
 T3 5(7.4) 1(0.8) 1(3.2)  
 T4a 51(75.0) 101(85.6) 23(74.2)  
 T4b 7(10.3) 5(4.2) 5(16.1)  
N stagea     0.230
 N0 8(11.8) 35(29.7) 5(16.1)  
 N1 13(19.1) 16(13.6) 7(22.6)  
 N2 16(23.5) 26(22.0) 6(19.4)  
 N3a 18(26.5) 21(17.8) 8(25.8)  
 N3b 13(19.1) 20(16.9) 5(16.1)  
  1. BMI body mass index, NACT neoadjuvant chemotherapy, LND lymph node dissection, LVI lymphovascular invasion, EGJ esophagogastric junction, E esophagus, U upper, M middle
  2. a7th UICC/AJCC TNM classification for gastric cancer